Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. Issue 8 (5th August 2020)

• Record Type: Journal Article
• Authors: Payne, Thomas; Sassani, Matilde; Buckley, Ellen; Moll, Sarah; Anton, Adriana; Appleby, Matthew; Maru, Seema; Taylor, Rosie; McNeill, Alisdair; Hoggard, N; Mazza, Claudia; Wilkinson, Iain D; Jenkins, Thomas; Foltynie, Thomas; Bandmann, O
• Is Part Of: BMJ open. Volume 10:Issue 8(2020)
• Publication Date: 2020-08-05
• Subjects: parkinson's disease -- neurology -- magnetic resonance imaging -- clinical trials -- adult neurology -- neuroradiology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-038911
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: There are no disease-modifying treatments for Parkinson's disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of this trial are to determine safety and tolerability of UDCA in PD at 30 mg/kg, confirm the target engagement of UDCA, apply a novel motion sensor-based approach to quantify disease progression objectively, and estimate the mean effect size and its variance on the change in motor severity. Methods and analysis: This is a phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA at a dose of 30 mg/kg in 30 participants with early PD. Treatment duration is 48 weeks, followed by an 8-week washout phase. Randomisation is 2:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48 and 56. The primary outcome is safety and tolerability. Secondary outcomes will compare the change between baseline and week 48 using the following three approaches: the Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 in the practically defined 'OFF' medication state; confirmation of target engagement, applying 31 Phosphorus MR Spectroscopy to assess the levels of ATP and relevant metabolites in the brain; and objective quantification of motor impairment, using a validated, motion sensor-based approach. The primary outcome will be reported using descriptive statistics and comparisons between treatment groups. For each secondary outcome, the change from baseline will be summarised within treatment groups using summary statistics and appropriate statistical tests assessing for significant differences. All outcomes will use an intention-to-treat analysis population. Ethics and dissemination: This trial has been approved by the East of England – Cambridgeshire and Hertfordshire Research Ethics committee. Results will be disseminated in peer-reviewed journals, presentations at scientific meetings and to patients in a lay-summary format. Trial registration number: NCT03840005 .